Insights from BCC Research

Companion Diagnostics Market Soars on Adoption of Liquid Biopsies

Posted by Laurie L. Sullivan on Apr 20, 2017 11:00:00 AM

Key to making personalized medicine a reality, companion diagnostics are playing a critical role in the accurate diagnosis of disease and are enabling the efficient use of targeted therapies. This highly complex sector continues to innovate, as exemplified by the development of liquid biopsy technology, which introduces a new, noninvasive, cost-effective way for clinicians to make treatment adjustments.

Read More

Topics: Life Sciences, Biotechnology

Infectious Diseases May Fuel China to Become Biggest Consumer of Drugs

Posted by Laurie L. Sullivan on Apr 12, 2017 10:00:00 AM

China is one of the world’s largest and fastest-growing drug markets. At a five-year compound annual growth rate (CAGR) of 14.0%, BCC Research predicts that the Chinese drug market will reach $424.3 billion by 2021. At this pace, China is likely to overtake the United States to become the world’s largest consumer of drugs by 2025.

Read More

Topics: Life Sciences, Pharmaceuticals

Asia-Pacific, Kidney Disease Spur Erythropoietin Biosimilars Market

Posted by Laurie L. Sullivan on Mar 28, 2017 10:30:00 AM

The global erythropoietin biosimilars market has been expanding rapidly in the past decade. This acceleration has primarily been the result of patent expiries of major erythropoietin biologics in the European market coupled with a demand for cheaper erythropoietin agents in the Asia-Pacific, South American, Middle Eastern, and African markets. BCC Research projects that over the next five years, the global market for erythropoietin biosimilars will continue to enjoy healthy gains while the global market for erythropoietin biologics (i.e., patented products) will shrink substantially.

Read More

Topics: Life Sciences, Pharmaceuticals

The Pendulum Swing of Generic Drug Prices

Posted by Laurie L. Sullivan on Feb 22, 2017 10:00:00 AM

pharma-1.jpgThe pharmaceutical industry is facing challenges and changes more radical than any in the past 50 years. The worldwide economic recession has had a profound impact on a sector that is normally resilient to market ups and downs. In addition to cutting costs and restructuring, the industry has had to confront the fact that its trading environment has fundamentally changed because its customers are more cost conscious than ever. At this critical time, the pharmaceutical world has also stumbled upon the so-called patent cliff: R&D pipelines have not been able to produce a sufficient supply of replacements for blockbuster drugs that have lost patent protection.

Read More

Topics: Life Sciences, Pharmaceuticals